FDA Medical Device Recall Concentration: Top 50 Firms Drive Over Half of All Recalls

Executive Summary

When procurement, supply-chain, and regulatory professionals think about medical device recall risk, the natural instinct is to look for the largest, most dangerous individual recall. But the public FDA record tells a more structural story: recall activity is highly concentrated among a small group of large manufacturers, layered over an extremely long tail of firms that recall a product only once. Our analysis of the full FDA Medical Device Recall database finds:

• The top 50 named manufacturers account for 52.4% of all recall records, the top 100 for 61.9%, and the top 10 alone for 28.3% — despite those top 50 firms representing only about 1% of all recalling firms.
• Zimmer Biomet leads with 2,940 recall records (5.2%), followed by Philips (2,212), Stryker (2,134), Siemens Healthineers (2,042), and Medtronic (1,897) — the imaging, orthopedic, and cardiovascular giants that sit at the center of the medtech market.
• The long tail is enormous: 3,916 distinct named firms appear in the recall record, but 1,631 of them (41.6%) have exactly one recall. A recall event is, for most firms, a one-off — while for a small group it is a recurring operational reality.
• Annual recall volume is stable-to-rising, with a clear pandemic trough: roughly 3,000-3,300 recalls per year before 2020, dropping to ~2,260-2,600 during 2020-2022, and recovering to 3,275 in 2024.

The practical takeaway is that recall risk is not evenly distributed across the medtech supplier base. Due-diligence frameworks that treat every supplier's recall exposure as equivalent will misprice risk; frameworks that weight recall frequency, recall class mix, and trend over time will align much more closely with the actual public record.

Why Concentration Matters for Medtech Supply Chains

The FDA recall database is, at root, a record of post-market quality-system failures: a manufacturer (or the FDA) determines that a distributed device is adulterated, misbranded, or otherwise violates the Federal Food, Drug, and Cosmetic Act, and initiates a correction or removal. Aggregated across the full database, those records reveal which firms carry the heaviest post-market quality burden.

That information is commercially significant in three directions. For group purchasing organizations and hospital value-analysis committees, a supplier's recall frequency is a direct indicator of the operational disruption a contract will impose — staff time on notifications, returns, and substitutes. For OEMs sourcing components or contract-manufactured assemblies, the same metric signals the maturity of a partner's quality system and the downstream risk to the OEM's own 510(k) holdership. For insurers and litigation teams, the concentration data contextualizes which device categories and firms are most likely to generate exposure. It also complements severity-focused analyses: a separate MedDeviceGuide review of Class I (life-threatening) enforcement trends covers the high-severity tail, whereas this analysis covers the full volume distribution across all classes.

Data Source and Method

• Analysis sample: 58,374 records from the FDA Medical Device Recall database (the "res" / product-recall extract), plus 39,096 records from the FDA device enforcement-report database for class and firm totals.
• Method: All counts were computed by MedDeviceGuide from public FDA extracts. Recalling-firm names were consolidated across corporate variants and legal-entity suffixes — for example, the multiple Zimmer, Biomet, and Zimmer Biomet entities were grouped under Zimmer Biomet; Siemens entities under Siemens Healthineers; DePuy and Johnson & Johnson orthopedic entities under DePuy / J&J; C.R. Bard and Bard entities under Bard; and Becton Dickinson entities under BD. Records with no recalling firm recorded (2.5% of the total) were excluded from the named-firm concentration counts but retained in the annual-volume totals. Shares are stated against named-firm records unless noted otherwise. Because firm counts here are consolidated across corporate and legal-entity variants, the firm-level rankings and concentration are higher than the lighter-consolidation firm figures cited in our broader FDA recall root-cause-trends analysis; the underlying 58,374-record dataset is the same, and the consolidation method is the reason the two views differ.

The Top Recallers: Imaging and Orthopedic Giants Lead

Across the named-firm recall record, the top manufacturers by recall volume are:

The leaderboard is dominated by two device families: orthopedic implants (Zimmer Biomet, Stryker, DePuy/J&J, Smith & Nephew) and imaging and capital equipment (Philips, Siemens Healthineers, GE HealthCare). Cardiovascular (Medtronic, Boston Scientific, Abbott, Bard) and infusion / drug-delivery (Baxter, ICU Medical, Arrow) firms round out the top tier. This is not a ranking of "worse" manufacturers so much as a reflection of where the recall volume sits: large, high-SKU-count portfolios in regulated categories with extensive installed bases generate more recall activity in absolute terms, and the orthopedic and imaging segments carry particularly large service and configuration burdens.

The Pareto Shape: 50 Firms, Half the Recalls

The concentration curve is steep but not extreme — a classic long-tail distribution rather than a near-monopoly:

Roughly half of all recall activity is attributable to 50 firms out of nearly 4,000. The other half is spread across the remaining 3,800+ firms — most of which appear only a handful of times. For benchmarking purposes, this means a useful "recall concentration" metric for a supplier is not merely "has the firm ever recalled" but "where does the firm sit on this curve" — specifically, whether its recall count is consistent with its portfolio scale or materially above peer firms of comparable size.

The Long Tail: Most Firms Recall Only Once

The flip side of the concentration is how thin the tail is at the level of the individual firm:

More than four in ten firms in the recall database appear exactly once. For these firms, a recall is a discrete quality event rather than a recurring operational feature — and the appropriate risk response (root-cause investigation, CAPA, supplier correction) differs from the response appropriate for a firm that appears hundreds of times. The same database logic that surfaces the top recallers should be used to avoid over-weighting a single historical recall when evaluating a long-tail supplier.

The Philips Anchor: When One Recall Becomes a Corporate-Defining Event

The concentration data also explains why individual recalls can reshape a company's risk profile. Philips' second-place ranking (2,212 recall records) is anchored by the June 2021 Philips Respironics recall of CPAP, BiPAP, and ventilator devices, driven by degradation of the polyester-based polyurethane (PE-PUR) sound-abatement foam. The FDA classified it as Class I, and the recall ultimately encompassed roughly 15 million devices worldwide, making it one of the largest medical device recalls in history.

The consequences were structural, not just operational: in 2024 a federal court entered a consent decree governing Philips Respironics' recall remediation, and Philips separately agreed to pay approximately $1.1 billion to resolve personal-injury and medical-monitoring litigation in multidistrict litigation (MDL 3014). A single product-family failure — a foam material decision — translated into years of recall records, regulatory oversight, and financial exposure. For supply-chain teams, the lesson is that the recall count for a top-tier firm can be dominated by one or two large episodic events, and the right diligence question is whether a firm's recall volume is driven by chronic, distributed quality issues or by a discrete incident under remediation.

Annual Volume: A Pandemic Trough and a Recovery

Total recall initiation by year shows a stable baseline with a clear pandemic disruption:

The 2020-2022 dip reflects both reduced elective-device utilization and reporting lags during the pandemic, not necessarily an improvement in device quality. The recovery to 3,275 records in 2024 aligns with independent industry reporting that 2024 represented a four-year high for medical device recall events. Notably, while total recall volume has been comparatively stable, the mix has shifted toward higher severity: FDA data and industry tracking indicate Class I recalls rose sharply over the 2020-2025 window even as overall event counts stayed within a familiar band. Volume and severity, in other words, are moving on different axes.

Class Distribution: Class II Dominates the Enforcement Record

Looking across the full device enforcement-report database (39,096 records), the class distribution reinforces why recall frequency and recall severity are distinct metrics:

Class II — moderate risk — accounts for nearly nine in ten enforcement actions. Class I, the level associated with a reasonable probability of serious adverse health consequences or death, is roughly 9%. This is why a volume-based concentration analysis (this article) and a severity-based analysis (Class I trends) can reach different conclusions about the same database: the firms that recall the most overall are not necessarily the firms that drive the most Class I events, and both lenses are needed to assess supplier risk honestly.

What This Means for Procurement, Quality, and Regulatory Teams

1. Weight recall frequency, not just recall existence. A supplier appearing once in the recall database is normal; a supplier appearing hundreds of times is a signal. Build supplier scorecards that rank firms against the concentration curve above, normalized for portfolio size, rather than treating any recall as disqualifying.
2. Separate chronic from episodic recall volume. Ask whether a top recaller's count is driven by distributed, recurring quality issues (a process-maturity problem) or by one or two large remediated incidents (a contained event). The Philips consent-decree example shows how a single incident can dominate a firm's record for years.
3. Pair volume with severity. Use this concentration analysis alongside Class I severity tracking. A supplier with modest total recall volume but a recent Class I event may carry more operational risk than a high-volume, predominantly Class II recaller.
4. Build the long tail into onboarding. Because 42% of recalling firms appear only once, a clean recall history is not strong evidence of a mature quality system for a smaller or newer supplier — it may simply mean limited operating history. Complement recall screening with QMS audit, CAPA effectiveness review, and complaint-handling assessment.

For regulatory affairs teams, the dataset is also a competitive-intelligence tool: the public recall record lets you benchmark a predicate or partner firm's post-market posture before committing to a 510(k) holderhip, distribution, or co-branding relationship.

Data sources: FDA Medical Device Recall database and FDA device enforcement report database; analysis by MedDeviceGuide, run date 2026-06-16. Recalling-firm names were consolidated across corporate and legal-entity variants; records with no recalling firm recorded (2.5% of the total) were excluded from named-firm concentration counts. Class totals are computed from the enforcement-report database, which assigns recall classifications that the recall database does not. This article is educational and is not regulatory, quality-system, legal, or commercial advice for a specific product or supplier.